X

Drug Profile

Monoclonal antibody TM31

Alternative Names: Monoclonal antibody TM 31; TM 31

Latest Information Update: 11 Apr 2005

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AVANT Immunotherapeutics
Developer AstraZeneca; AVANT Immunotherapeutics
Class Antirheumatics; Monoclonal antibodies
Mechanism of Action Immunosuppressants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Rheumatoid arthritis

Most Recent Events

11 Apr 2005 Discontinued - Preclinical for Rheumatoid arthritis in Sweden (unspecified route)
11 Apr 2005 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)
07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com